Physician profile
Massie Headley
NPI 1649249426
$10,477.73
in general payments reported to CMS, 2019-2025
51 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $1,222 · 2021: $1,552 · 2022: $1,454 · 2023: $1,266 · 2024: $1,448 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,391.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,329.99 | 2019-2025 | |
| Abbvie INC. | $1,300.42 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $806.16 | 2019-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $733.00 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $723.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $683.08 | 2019-2020 | |
| Lilly USA, LLC | $571.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $467.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $412.76 | 2019-2025 | Dificid, Capvaxive, Gardasil 9 |
| Glaxosmithkline, LLC. | $364.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $294.50 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $247.77 | 2020-2021 | |
| Amgen INC. | $234.55 | 2019-2025 | Repatha, Otezla, Repatha |
| Axsome Therapeutics, INC. | $208.38 | 2023-2025 | Auvelity, Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.09 | 2019-2024 | Xifaxan, Trulance |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Massie Headley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.